Primary thyroid diffuse large B-cell lymphoma: a case report and focused review of the literature.

Ann HematolOct 9, 2026 (epub)

Kürsat Kirkgöz, Katja Weisel, Carsten Bokemeyer et al.

✦ AI-curated · Sources linked

Case in brief

A 74-year-old woman presented with dyspnoea, hoarseness, and cough and was diagnosed with primary thyroid non-GCB-type diffuse large B-cell lymphoma, stage IE (IPI 2). R-CHOP with CNS prophylaxis achieved complete remission. Six years later, lymphoma relapsed in the contralateral thyroid gland without reported disease elsewhere. Off-label Pola-R-miniCHP treatment led to a second complete remission.

What made this case unusual

The relapse was isolated to the opposite thyroid gland after a six-year remission, rather than being reported at another site.

Diagnostic / clinical pearl

Reliable histopathological characterization of suspected primary thyroid lymphoma may require core needle or surgical biopsy; the review notes that surgery was largely used for diagnosis.

Why it matters

The authors highlight the limited evidence-based guidance for primary thyroid DLBCL and the need for registry-based studies, particularly of primary extranodal DLBCL, to inform treatment guidelines.

Source

Published in Ann Hematol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.